merck & co. - Search News

Merck, Keytruda and Cancer Drug

New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling a new version of its drug Keytruda.

Reuters on MSN · 22h

New version of Merck's Keytruda faces possible patent battle, WSJ reports

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.

Business Insider · 1d

Merck (MRK) Battling to Protect Key Cancer Drug as Patent Row Heats Up

Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a new version of

Seeking Alpha on MSN · 1d

Merck set for patent battle with Halozyme over injectable Keytruda: WSJ

A new patent dispute is brewing between Halozyme Therapeutics (NASDAQ:HALO), a biotech focused on drug delivery technology, and Merck (NYSE:MRK) over an injectable version of the New Jersey-based pharma giant’s cancer blockbuster,

18hon MSN

Merck & Co. (MRK): An Undervalued Wide Moat Stock to Buy According to Analysts

We recently compiled a list of the 12 Undervalued Wide Moat Stocks to Buy According to Analysts. In this article, we are ...

Delaware approves $30.2 million taxpayer-funded grant for Merck to build in state

The state of Delaware has offered Merck a $30.2 million grant to encourage the company to choose the Wilmington-area location. If Merck accepts the grant, the company would be required to create 375 ...

3MRK : Spotlight on Merck & Co: Analyzing the Surge in Options Activity

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Merck & Co. Inc. stock outperforms competitors on strong trading day

Merck & Co. Inc. closed 32.72% below its 52-week high of $134.63, which the company achieved on June 25th.

MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!

NEW YORK CITY, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Merck & Co.'s Real Value: A Deep Dive Into Its Fundamentals

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

Fierce Biotech4h

Merck KGaA fails midphase lupus trial, says totality of data support further development

One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...

TOP RANKED ROSEN LAW FIRM Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class ...